If you have been reading about GLP-1 analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Especially since 2023, Xi has also overseen significant anti-corruption efforts in the military, with some targets involving those that rose to prominence under his leadership. Those targeted included former defense ministers Li Shangfu and Wei Fenghe, CMC vice chairmen He Weidong and Zhang Youxia, and CMC member Miao Hua. In addition, former Xinjiang Party Secretary and Politburo member Ma Xingrui was put under investigation in 2026. Bloomberg News estimated that as October 2025, at least 14 generals out of 79 appointed under Xi's leadership have been ousted. Xi has introduced stringent restrictions on naked officials, CCP officials with spouses or children residing abroad, eventually culminating in a 2025 campaign to require cadres of vice-ministerial rank or above being required to either repatriate family members or resign from office.
Newborn hearing testing is done at the bedside using transiently evoked otoacoustic emissions, automated auditory brainstem responses, or a combination of both techniques. Hearing screening programs have found the initial testing to cost between $10.20 and $23.37 per baby, depending on the technology used. As these are screening tests only, false positive results will occur. False positive results could be due to user error, a fussy baby, environmental noise in the testing room, or fluid or congestion in the outer/middle ear of the baby. A review of hearing screening programs found varied initial referral rates (screen positive results) from 0.6% to 16.7%. The highest overall incidence of hearing loss detection was 0.517%. A significant proportion of screen positive infants were lost to follow-up before a diagnosis could be confirmed or ruled out in all screening programs.
In 1997, cannabis was estimated to be overall the number four value crop in the US, and number one or two in many states, including California, New York, and Florida. This estimate is based on a value to growers of ~60% of retail value, or $3,000 per pound ($6,600/kg). In 2006, cannabis was estimated to have been a $36 billion market. This estimate has been challenged as exaggerated. The UN World Drug Report (2008) estimated that 2006 street prices in the US and Canada ranged from about US$8.8 to $25 per gram (approximately $250 to $700 per ounce), depending on quality. Typical U.S. retail prices were $10–15 per gram (approximately $280–420 per ounce). In 2017, the U.S. was estimated to constitute 90% of the worldwide $9.5 billion legal trade in cannabis. After some U.S. states legalized cannabis, street prices began to drop. In Colorado, the price of smokable buds (infructescences) dropped 40 percent between 2014 and 2019, from $200 per ounce to $120 per ounce ($7 per gram to $4.19 per gram). The European Monitoring Centre for Drugs and Drug Addiction reports that typical retail prices in Europe for cannabis varied from €2 to €20 per gram in 2008, with a majority of European countries reporting prices in the range €4–10.
== Career == Following his Doctoral degree, Greenspan joined Yale University School of Medicine as a Postdoctoral fellow in the Department of Genetics. In 1984, he was appointed as an Associate Research Scientist in the Department of Genetics and was supported by a fellowship from the Arthritis Foundation. His postdoctoral studies at Yale included analysis of RNA splicing and identification of new human HLA genes. He subsequently joined the University of Wisconsin-Madison School of Medicine in 1986 as assistant professor in the Department of Pathology and Laboratory Medicine. Greenspan was promoted to Associate Professor in 1992, and became a Professor in 1997. From 2010 – 2014 Greenspan served as founding/interim chair of the Department of Cell and Regenerative Biology at the University of Wisconsin School of Medicine and Public Health. Prior to that, he was Vice Chair for Research in the Department of Pathology and Laboratory Medicine from 2003 to 2006.
According to the marketeer, the old name "McDonald's" will soon disappear from the lexicon of the Russian consumers, and, to not pronounce the long phrase, clients of the chain will make up their own. On 13 June, various messages appeared claiming that the logo of Vkusno i tochka is a lazy alteration of a Portuguese pet food brand "Matosmix". On 15 June, the director of a fast food chain known as "Food, full stop" (Russian: Еда и точка) in Primorsky Krai, Sergei Ponkratov, accused the new chain of plagiarism and decided to sue it, demanding a change of the name. He claims that the Vkusno i tochka brand clearly intersects with and deprives his trademark, which has been operating since 2018, of uniqueness and recognizability.
Sources: en.wikipedia.org
But when histidine18, the ε-amino group of lysine4 and the α-amino group of cysteine1 all are carbethoxylated and acetylated toxicity decreases drastically. This means that these three amino acids are not essential for toxicity on their own, but the three of them combined are. Chemical alteration of arginine13 and arginine14 by treatment of 1,2-cyclohexanedione and cleavage by trypsin decreases toxicity by a factor greater than 10. The amino acids that cause toxicity of apamin are cysteine1, lysine4, arginine13, arginine14 and histidine18.
Prolactin also self-regulates through a counter-current flow in the hypophyseal pituitary portal system, which triggers the release of hypothalamic dopamine. This process also inhibits the pulsatile secretion of gonadotropin-releasing hormone (GnRH), thereby negatively influencing the secretion of pituitary hormones that regulate gonadal function. Estrogen promotes the growth of pituitary lactotroph cells, particularly during pregnancy. However, lactation is hindered by the elevated levels of estrogen and progesterone during this period. The rapid decline in estrogen and progesterone after childbirth enables lactation to begin. While breastfeeding, prolactin suppresses gonadotropin secretion, potentially delaying ovulation. Ovulation may resume before the return of menstruation during this time. Although hyperprolactinemia can result from normal physiological changes during pregnancy and breastfeeding, it can also be caused by other etiologies. For example, high prolactin levels could result from diseases affecting the hypothalamus and pituitary gland. Other organs, such as the liver and kidneys, could affect prolactin clearance and consequently, prolactin levels in the serum. The disruption of prolactin regulation could also be attributed to external sources such as medications. In the general population, the prevalence of hyperprolactinemia is 0.4%. The prevalence increases to as high as 17% in women with reproductive diseases, such as polyendocrine metabolic ovarian syndrome.
In the process, he found that a precipitation of thorium A (polonium-216) and thorium B (lead-212) also contained a short-lived "element", which he named thorium C (which was later identified as polonium-212). Hahn was unable to separate it, and concluded that it had a very short half-life (it is about 300 ns). He also identified radioactinium (thorium-227) and radium D (later identified as lead-210). Rutherford remarked that: "Hahn has a special nose for discovering new elements."
Bitcoin (abbreviation: BTC; sign: ₿) is the first decentralized cryptocurrency. Based on a free-market ideology, bitcoin was invented in 2008 when an unknown person published a white paper under the pseudonym of Satoshi Nakamoto. Use of bitcoin as a currency began in 2009, with the release of its open-source implementation. From 2021 to 2025, El Salvador adopted it as legal tender currency before revoking it. As bitcoin is pseudonymous, its use by criminals has attracted the attention of regulators, leading to its ban by several countries. Bitcoin works through the collaboration of computers, each of which acts as a node in the peer-to-peer bitcoin network. Each node maintains an independent copy of a public distributed ledger of transactions, called a blockchain, without central oversight. Transactions are validated through the use of cryptography, preventing one person from spending another person's bitcoin, as long as the owner of the bitcoin keeps certain sensitive data secret. Consensus between nodes about the content of the blockchain is achieved using a computationally intensive process based on proof of work, called mining, which is performed by purpose-built computers. Mining consumes large quantities of electricity, with surveyed miners reporting that 52% of their electricity use came from sustainable energy sources, and has been criticized for its environmental impact.
== History == The American professional wrestling promotion WWE (formerly World Wrestling Federation, or WWF) has been broadcasting pay-per-view (PPV) events since the mid 1980s, when its classic "Big Four" events (Royal Rumble, WrestleMania, SummerSlam, and Survivor Series) were first established between 1985 and 1989—with the company's very first PPV being WrestleMania in 1985. The company's PPV lineup expanded to a monthly basis in 1995 following the introduction of the In Your House series of pay-per views (which were replaced by standalone ppvs in 1999) before expanding even further in the mid-2000s during the first WWE brand extension. In addition, WWE produced international PPVs not available in the United States between 1997 and 2003. In 2022, the company began recognizing Money in the Bank as one of their five biggest events of the year, thus making it a "Big Five" event along with the classic "Big Four"; King of the Ring was considered a "Big Five" event from 1993 until 2002, after which, it was discontinued as a PPV until 2024. Following WWE's original brand extension in 2002, the company promoted two touring rosters, Raw and SmackDown, representing its television programs, Raw and SmackDown, with the two United Kingdom PPVs held that year being the first ones to be brand exclusive. Following Judgment Day in 2003, brand-exclusive PPVs were expanded to all WWE PPVs, except the traditional "Big Four", which continued to showcase the entire roster, while the remaining PPVs alternated between Raw and SmackDown.
Sources: en.wikipedia.org
=== Part Two === Part Two begins some time before Part One, taking place somewhere before the chapter Anticitizen One during the final events of Half-Life 2. During the battle for City 17, a Russian Resistance member (Julia Tourianski) is about to be killed by CP officers when the third Resistance member (David Purchase), who was only heard in a radio transmission during Part One, saves her by killing the officers. At first, she doesn't trust him, but after partnering up together to survive the battle, they become closer to each other. At one point in the film, they kiss in an abandoned restroom after destroying a Combine Strider. Sometime later, David gives Julia a present: a 9mm pistol with the slogan "Never Gone" written on the side. She starts to weep, because she hadn't been "given a gift in over a decade." Soon after, the final events of Half-Life 2, as well as the chapters Undue Alarm and Direct Intervention of Episode One, come to pass, and the Citadel's dark energy reactor begins to enter meltdown. However, Gordon Freeman's actions delay the reaction long enough to allow citizens and Resistance members alike to escape City 17. David and Julia decide to leave the city as well. After reaching the old canals and combating zombies, the first two Resistance members from Part One, Derek and Ian, finally catch up with the duo. As they walk together, they talk about Freeman's actions within the Citadel. Suddenly, David is shot in the neck by a CP officer. As the other two members fire back at the incoming Combine soldiers, David dies in Julia's arms.
=== World production of ethylene oxide === The world production of ethylene oxide was 20 Mt (22 million short tons) in 2009, 19 Mt (21 million short tons) in 2008 and 18 Mt (20 million short tons) in 2007. This places ethylene oxide 14th most produced organic chemical, whereas the most produced one was ethylene with 113 Mt (125 million short tons). SRI Consulting forecasted the growth of consumption of ethylene oxide of 4.4% per year during 2008–2013 and 3% from 2013 to 2018. In 2004, the global production of ethylene oxide by region was as follows:
=== Sex organs === Hydrostatic penises have convergently evolved at least six times in male amniotes. In these species, males copulate with females and internally fertilize their eggs. Similar intromittent organs have evolved in invertebrates such as octopuses and gastropods.
In 2020, potassium was the 33rd most commonly prescribed medication in the U.S., with more than 17 million prescriptions. Other uses of potassium supplements include preventing the formation of kidney stones, a condition that can lead to renal complications if left untreated. Potassium has a role in bone health. It contributes to the acid-base equilibrium in the body and helps protect bone tissue. For individuals with type 2 diabetes, potassium supplementation may be necessary: potassium is essential for the secretion of insulin by pancreatic beta cells, which helps regulate glucose levels. Excessive potassium intake can have adverse effects, such as gastrointestinal discomfort and disturbances in heart rhythm. Potassium chloride tablets are specifically associated with pill esophagitis.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.